アボット・ラボラトリーズ
Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed in the United States as "Teveten" by Abbvie, the spin-off of the pharmaceutical discovery division of Abbott Laboratories; it is marketed as "Eprozar" by Intas Pharmaceuticals in India, and by Abbott Laboratories elsewhere. The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.